1. Immunology/Inflammation
  2. PD-1/PD-L1

PD-1/PD-L1

Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.

Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.

In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.

PD-1/PD-L1 Related Products (27):

Cat. No. Product Name Effect Purity
  • HY-19745
    BMS-202 Inhibitor 98.45%
    BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity[1][2].
  • HY-P9904
    Atezolizumab Inhibitor 98.98%
    Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-100022
    Tomivosertib Inhibitor 99.49%
    Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines[1]. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance[2].
  • HY-P9903
    Nivolumab Inhibitor 98.56%
    Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.
  • HY-P9902
    Pembrolizumab Inhibitor 99.06%
    Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
  • HY-131347
    PD-1/PD-L1-IN-NP19 Inhibitor
    PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects[1].
  • HY-129172A
    PD-1/PD-L1-IN 5 Inhibitor
    PD-1/PD-L1-IN 5 is a PD-1/PD-L1 protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC50 of ≤100 nM[1].
  • HY-131183
    PROTAC PD-1/PD-L1 degrader-1 Inhibitor
    PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 degrader, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner[1].
  • HY-19991
    BMS-1 Inhibitor 99.61%
    BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM)[1][2].
  • HY-101093
    PD-1-IN-1 Inhibitor 99.63%
    PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO2015033299A1, compound example 4. PD-1-IN-1 can be used as immune modulator[1].
  • HY-108730
    Avelumab Inhibitor 99.20%
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
  • HY-102011
    BMS-1166 Inhibitor 99.86%
    BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation[1][2].
  • HY-P9919
    Durvalumab Inhibitor 99.60%
    Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody[1]. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively[2].
  • HY-120635
    BMS-1001 hydrochloride Inhibitor 98.46%
    BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cells[1].
  • HY-N0242
    Fraxinellone Inhibitor 99.99%
    Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1[1].
  • HY-P1812A
    AUNP-12 TFA Antagonist
    AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)[1].
  • HY-101097
    PD-1-IN-17 Inhibitor
    PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM[1].
  • HY-B1387
    Sulfamethoxypyridazine Inhibitor 99.01%
    Sulfamethoxypyridazine is a long-acting sulfonamide antibiotic, for treatment of Dermatitis herpetiformis.
  • HY-101098
    PD-1-IN-18 Inhibitor
    PD-1-IN-18 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.
  • HY-103048A
    PD-1/PD-L1-IN 3 TFA Inhibitor
    PD-1/PD-L1-IN 3 TFA is a PD-1/PD-L1 interaction inhibitor extracted from patent WO2014151634A1, compound 1. PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM[1].